Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.

@article{Pan2015InhibitionOM,
  title={Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.},
  author={Rongqing Pan and Vivian R Ruvolo and Jun Koh Wei and Marina Y Konopleva and John C. Reed and Maurizio Pellecchia and Michael Andreeff and Peter P Ruvolo},
  journal={Blood},
  year={2015},
  volume={126 3},
  pages={
          363-72
        }
}
Overexpression of antiapoptotic Bcl-2 proteins such as Bcl-2, Bcl-xL, and Mcl-1 is widely associated with tumor initiation, progression, and chemoresistance. Furthermore, it has been demonstrated that Mcl-1 upregulation renders several types of cancers resistant to the Bcl-2/Bcl-xL inhibitors ABT-737 and ABT-263. The emerging importance of Mcl-1 in pathogenesis and drug resistance makes it a high-priority therapeutic target. In this study, we showed that inhibition of Mcl-1 with a novel pan-Bcl… CONTINUE READING
Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 35 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 57 REFERENCES

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with BLOOD, 16 JULY 2015 x VOLUME 126, NUMBER 3 Mcl-1 INHIBITION OVERCOMES ABT-737 RESISTANCE

  • L Gandhi, DR Camidge, M Ribeiro de Oliveira
  • For personal use only. on April
  • 2017
1 Excerpt

Similar Papers

Loading similar papers…